Anavex Life Sciences (AVXL) Operating Income (2021 - 2025)
Anavex Life Sciences (AVXL) reported Operating Income of -$5.7 million for Q4 2025, up 58.34% on a YoY basis from -$3.6 million in Q4 2024, and up 47.78% sequentially from -$10.8 million in Q3 2025.
Anavex Life Sciences (AVXL) Operating Income (2021 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 5 years of Operating Income data on file, last reported at -$5.7 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Income rose 58.34% year-over-year to -$5.7 million; the trailing twelve-month figure through Dec 2025 stood at -$43.5 million (up 21.08% YoY), and the FY2025 full-year result was -$51.4 million, up 2.78% from the prior year.
- Operating Income advanced to -$5.7 million in Q4 2025, from -$10.8 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$5.7 million in Q4 2025 to a low of -$15.4 million in Q4 2022.
- A 5-year average of -$12.7 million and a median of -$12.7 million in 2023 frame the typical range for Operating Income.
- Across the five-year window, Operating Income slumped 31.22% in 2022 and surged 58.34% in 2025, its largest moves.
- Tracing AVXL's Operating Income over 5 years: stood at -$11.7 million in 2021, then slumped by 31.22% to -$15.4 million in 2022, then rose by 26.04% to -$11.4 million in 2023, then slipped by 19.46% to -$13.6 million in 2024, then surged by 58.34% to -$5.7 million in 2025.
- Business Quant data shows AVXL's Operating Income at -$5.7 million in Q4 2025, -$10.8 million in Q3 2025, and -$14.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Anavex Life Sciences | 214.12 Mn | 82.37 Mn | - | -5.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.66 Mn |
| Sep 30, 2025 | -10.84 Mn |
| Jun 30, 2025 | -14.46 Mn |
| Mar 31, 2025 | -12.51 Mn |
| Dec 31, 2024 | -13.59 Mn |
| Sep 30, 2024 | -14.27 Mn |
| Jun 30, 2024 | -14.60 Mn |
| Mar 31, 2024 | -12.62 Mn |
| Dec 31, 2023 | -11.38 Mn |
| Sep 30, 2023 | -12.66 Mn |
| Jun 30, 2023 | -13.53 Mn |
| Mar 31, 2023 | -14.19 Mn |
| Dec 31, 2022 | -15.38 Mn |
| Sep 30, 2022 | -15.28 Mn |
| Jun 30, 2022 | -12.46 Mn |
| Mar 31, 2022 | -11.52 Mn |
| Dec 31, 2021 | -11.72 Mn |